2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 6 000 | ||
| 1 500 | ||
| 523 | ||
| 5 952 | ||
| 7 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·7 t sittenSTENOCARE reports 53% revenue growth in Q3 2026 and maintains ambition for positive full-year EBITDA STENOCARE delivered significant revenue growth in the third quarter of 2026, driven by strong performance in the Danish core market. Regulatory changes in Germany and a temporary drop in earnings, however, ended a streak of positive quarterly EBITDA results, although the company continues to aim for a profitable full year. Looking ahead, the company is actively working to secure its supply chain for dried flowers and prepare for new opportunities in France. Net revenue in Q3 increased by 53 % year-on-year to 2.935 million DKK, while revenue for the first nine months increased by 125 % to 9.935 million DKK. EBITDA for the quarter was negative by 244 thousand DKK, ending five consecutive quarters of positive EBITDA, although EBITDA for the full year is still expected to be positive. Cash flow from operations for the first nine months of 2026 was positive by 0.8 million DKK, and cash and cash equivalents amounted to 0.6 million DKK as of 30 September 2026. The company is actively seeking alternative suppliers to mitigate potential supply shortages for Bedrocan products from 2027 onwards as a result of changes in Dutch export policy. Sales in Germany were below expectations due to changes in prescription and reimbursement requirements, but the company continues its commercial and educational efforts there. https://www.nordnet.dk/markedet/nyheder/ad687fac-db3c-4dbc-9008-1ca5d7f59cfd
- ·22.10.stock status Privatrezept reports sold out at a pharmacy Flowzs also reports sold out at a pharmacy Canngo reports sold out again, at the same pharmacy, within a short time. Now it is clear that the relaxations just passed in Germany have kick-started prescriptions with Weeco Astrum 10/10.
·21.10.Has any news come out since the price is rising. I have tried to find a reason, but can't find anything.stenocare is a very small and very illiquid stock, and typical for them is that they can swing incredibly much, up or down, from one moment, from one day to the next, and that on quite low turnover. Indtil videre ser jeg som et tilfældigt udsving.- ·21.10.lager status Med can one stop har udsolgt på et apotek Privat recepter melder også udsolgt på er apotek Canngo melder udsolgt på yderligere 1 apotek weed.dk melder udsolgt udsolgt på 2 apoteker. Det ser ud til, at de omtalte lempelser, så småt har sat gang i salget af Weeco Astrum 10/10 i Tyskland .
- ·21.10. · MuokattuIt is the parent company that is closing SynBiotic SE. It is old news that SynBiotic SE has had problems for a long time, and that Weeco Pharma is the only one of their companies that actually makes a profit. Everyone who has followed even a little bit knows this. SynBiotic SE bought Weeco Pharma 2024 with money they raised through a share emission, they had financial problems before they bought Weeco Pharma. SynBiotic SE has been closing down various companies, one by one that were in trouble. Meaning all except Weeco Pharma. SynBiotic has filed for bankruptcy on October 16, 2026 That Weeco Pharma is not affected by a parent company's bankruptcy is due to the way corporate structures and German bankruptcy law are put together. It shouldn't be you, Dennis365, who came with this news, but PJ, so that he could immediately reassure the market with the above, which I have written. Yet another mistake that a competent CEO would not make. It is time for the board to put their foot down for PJ and find a new CEO who can drive Stenocare safely into the commercial world. I cannot post links to the above because it is several events that have led to their bankruptcy, but feel free to run it through AI.Thanks munchini It is TS who is CEO and PJ who is CFO. I cannot edit the post itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 196 218 | 196 218 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 196 218 | 196 218 | 0 | 0 |
2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·7 t sittenSTENOCARE reports 53% revenue growth in Q3 2026 and maintains ambition for positive full-year EBITDA STENOCARE delivered significant revenue growth in the third quarter of 2026, driven by strong performance in the Danish core market. Regulatory changes in Germany and a temporary drop in earnings, however, ended a streak of positive quarterly EBITDA results, although the company continues to aim for a profitable full year. Looking ahead, the company is actively working to secure its supply chain for dried flowers and prepare for new opportunities in France. Net revenue in Q3 increased by 53 % year-on-year to 2.935 million DKK, while revenue for the first nine months increased by 125 % to 9.935 million DKK. EBITDA for the quarter was negative by 244 thousand DKK, ending five consecutive quarters of positive EBITDA, although EBITDA for the full year is still expected to be positive. Cash flow from operations for the first nine months of 2026 was positive by 0.8 million DKK, and cash and cash equivalents amounted to 0.6 million DKK as of 30 September 2026. The company is actively seeking alternative suppliers to mitigate potential supply shortages for Bedrocan products from 2027 onwards as a result of changes in Dutch export policy. Sales in Germany were below expectations due to changes in prescription and reimbursement requirements, but the company continues its commercial and educational efforts there. https://www.nordnet.dk/markedet/nyheder/ad687fac-db3c-4dbc-9008-1ca5d7f59cfd
- ·22.10.stock status Privatrezept reports sold out at a pharmacy Flowzs also reports sold out at a pharmacy Canngo reports sold out again, at the same pharmacy, within a short time. Now it is clear that the relaxations just passed in Germany have kick-started prescriptions with Weeco Astrum 10/10.
- ·21.10.Has any news come out since the price is rising. I have tried to find a reason, but can't find anything.stenocare is a very small and very illiquid stock, and typical for them is that they can swing incredibly much, up or down, from one moment, from one day to the next, and that on quite low turnover. Indtil videre ser jeg som et tilfældigt udsving.
- ·21.10.lager status Med can one stop har udsolgt på et apotek Privat recepter melder også udsolgt på er apotek Canngo melder udsolgt på yderligere 1 apotek weed.dk melder udsolgt udsolgt på 2 apoteker. Det ser ud til, at de omtalte lempelser, så småt har sat gang i salget af Weeco Astrum 10/10 i Tyskland .
- ·21.10. · MuokattuIt is the parent company that is closing SynBiotic SE. It is old news that SynBiotic SE has had problems for a long time, and that Weeco Pharma is the only one of their companies that actually makes a profit. Everyone who has followed even a little bit knows this. SynBiotic SE bought Weeco Pharma 2024 with money they raised through a share emission, they had financial problems before they bought Weeco Pharma. SynBiotic SE has been closing down various companies, one by one that were in trouble. Meaning all except Weeco Pharma. SynBiotic has filed for bankruptcy on October 16, 2026 That Weeco Pharma is not affected by a parent company's bankruptcy is due to the way corporate structures and German bankruptcy law are put together. It shouldn't be you, Dennis365, who came with this news, but PJ, so that he could immediately reassure the market with the above, which I have written. Yet another mistake that a competent CEO would not make. It is time for the board to put their foot down for PJ and find a new CEO who can drive Stenocare safely into the commercial world. I cannot post links to the above because it is several events that have led to their bankruptcy, but feel free to run it through AI.Thanks munchini It is TS who is CEO and PJ who is CFO. I cannot edit the post itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 6 000 | ||
| 1 500 | ||
| 523 | ||
| 5 952 | ||
| 7 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 196 218 | 196 218 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 196 218 | 196 218 | 0 | 0 |
2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·7 t sittenSTENOCARE reports 53% revenue growth in Q3 2026 and maintains ambition for positive full-year EBITDA STENOCARE delivered significant revenue growth in the third quarter of 2026, driven by strong performance in the Danish core market. Regulatory changes in Germany and a temporary drop in earnings, however, ended a streak of positive quarterly EBITDA results, although the company continues to aim for a profitable full year. Looking ahead, the company is actively working to secure its supply chain for dried flowers and prepare for new opportunities in France. Net revenue in Q3 increased by 53 % year-on-year to 2.935 million DKK, while revenue for the first nine months increased by 125 % to 9.935 million DKK. EBITDA for the quarter was negative by 244 thousand DKK, ending five consecutive quarters of positive EBITDA, although EBITDA for the full year is still expected to be positive. Cash flow from operations for the first nine months of 2026 was positive by 0.8 million DKK, and cash and cash equivalents amounted to 0.6 million DKK as of 30 September 2026. The company is actively seeking alternative suppliers to mitigate potential supply shortages for Bedrocan products from 2027 onwards as a result of changes in Dutch export policy. Sales in Germany were below expectations due to changes in prescription and reimbursement requirements, but the company continues its commercial and educational efforts there. https://www.nordnet.dk/markedet/nyheder/ad687fac-db3c-4dbc-9008-1ca5d7f59cfd
- ·22.10.stock status Privatrezept reports sold out at a pharmacy Flowzs also reports sold out at a pharmacy Canngo reports sold out again, at the same pharmacy, within a short time. Now it is clear that the relaxations just passed in Germany have kick-started prescriptions with Weeco Astrum 10/10.
- ·21.10.Has any news come out since the price is rising. I have tried to find a reason, but can't find anything.stenocare is a very small and very illiquid stock, and typical for them is that they can swing incredibly much, up or down, from one moment, from one day to the next, and that on quite low turnover. Indtil videre ser jeg som et tilfældigt udsving.
- ·21.10.lager status Med can one stop har udsolgt på et apotek Privat recepter melder også udsolgt på er apotek Canngo melder udsolgt på yderligere 1 apotek weed.dk melder udsolgt udsolgt på 2 apoteker. Det ser ud til, at de omtalte lempelser, så småt har sat gang i salget af Weeco Astrum 10/10 i Tyskland .
- ·21.10. · MuokattuIt is the parent company that is closing SynBiotic SE. It is old news that SynBiotic SE has had problems for a long time, and that Weeco Pharma is the only one of their companies that actually makes a profit. Everyone who has followed even a little bit knows this. SynBiotic SE bought Weeco Pharma 2024 with money they raised through a share emission, they had financial problems before they bought Weeco Pharma. SynBiotic SE has been closing down various companies, one by one that were in trouble. Meaning all except Weeco Pharma. SynBiotic has filed for bankruptcy on October 16, 2026 That Weeco Pharma is not affected by a parent company's bankruptcy is due to the way corporate structures and German bankruptcy law are put together. It shouldn't be you, Dennis365, who came with this news, but PJ, so that he could immediately reassure the market with the above, which I have written. Yet another mistake that a competent CEO would not make. It is time for the board to put their foot down for PJ and find a new CEO who can drive Stenocare safely into the commercial world. I cannot post links to the above because it is several events that have led to their bankruptcy, but feel free to run it through AI.Thanks munchini It is TS who is CEO and PJ who is CFO. I cannot edit the post itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 6 000 | ||
| 1 500 | ||
| 523 | ||
| 5 952 | ||
| 7 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 196 218 | 196 218 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 196 218 | 196 218 | 0 | 0 |